Source comparison
Melanotan-2 vs PT-141: Research Application Comparison
Primary Receptor Targets MC1R, MC2R, MC3R, MC4R, MC5R (non-selective) MC3R and MC4R (selective, 50-fold preference over MC1R) PT-141's selectivity eliminates pigmentation. Critical for sexual dysfunction research where tanning is an unwanted confound Tanning E
This comparison does not assign a generated winner or score.
- Primary Receptor Targets
- MC1R, MC2R, MC3R, MC4R, MC5R (non-selective)
- MC3R and MC4R (selective, 50-fold preference over MC1R)
- PT-141's selectivity eliminates pigmentation. Critical for sexual dysfunction research where tanning is an unwanted confound
- Tanning Effect
- Visible skin darkening within 7–10 days at 0.5–1.0 mg daily; cumulative melanin production
- No pigmentation changes at any dose. MC1R affinity too low to trigger melanogenesis
- Melanotan-2 is the only viable option for UV-independent tanning research
- Sexual Function Effects
- Spontaneous arousal and erectile function via MC4R; onset within 2–4 hours; not dose-titratable for this effect alone
- Dose-dependent sexual desire and genital arousal; onset 45–90 minutes; designed specifically for on-demand use
- PT-141's predictable arousal window and absence of spontaneous erections make it superior for controlled sexual dysfunction studies
- Appetite Suppression
- Significant MC3R/MC4R-mediated appetite reduction; 15–25% caloric intake decrease in research models
- Minimal to no appetite effect. MC3R activation insufficient at sexual function doses
- Melanotan-2 has potential metabolic research applications PT-141 does not
- Typical Dosing
- 0.25–1.0 mg subcutaneous daily (loading), then 2–3× weekly (maintenance)
- 1.75 mg subcutaneous 45 minutes before activity; maximum 8 doses/month
- Melanotan-2 requires cumulative dosing; PT-141 is acute on-demand administration
- Nausea Incidence
- 40–60% during first week; typically resolves with continued use
- 40% per dose; transient (resolves within 4–6 hours)
- Both peptides cause nausea through central MC4R activation. Neither has an advantage here
- Regulatory Status
- Not FDA-approved; available as research peptide only
- FDA-approved as Vyleesi for female hypoactive sexual desire disorder
- PT-141 has completed Phase 3 trials and formal safety review; Melanotan-2 has not